IS26介导blaOXA-1和blaCTX-M-15扩增伴随外膜孔蛋白破坏与复发性菌血症中碳青霉烯耐药新发相关
该研究基于美国休斯顿ESBL-E菌血症队列,采用长读长与短读长测序及连续传代实验,揭示IS26介导的blaOXA-1和blaCTX-M-1组基因扩增同时插入孔蛋白基因导致孔蛋白失活,从而从ESBL-E背景新发非碳青霉烯酶CRE,且该扩增在无抗生素压力下稳定。
要点
- IS26介导的β-内酰胺酶基因扩增与孔蛋白破坏共同驱动非碳青霉烯酶CRE新发。
- 该耐药表型及基因扩增可在厄他培南压力下通过传代重现。
- 临床非CP-CRE分离株在无厄他培南暴露时耐药表型稳定。
核心结论
- IS26介导的β-内酰胺酶基因扩增与外膜孔蛋白破坏共同驱动临床非碳青霉烯酶CRE的新发。
- 这些扩增在无抗菌药物压力下保持稳定。
- 长读长测序可用于识别驱动耐药性的独特移动遗传元件机制。
研究设计与样本
- 研究美国休斯顿ESBL-E菌血症队列。
- 采用Oxford Nanopore长读长和Illumina短读长测序进行比较基因组分析。
- 对临床ST131大肠埃希菌分离株进行连续传代实验以重现体内观察。
- 使用qPCR和qRT-PCR分别测定β-内酰胺酶基因拷贝数和转录水平。
主要发现
- 非碳青霉烯酶CRE临床分离株从ESBL-E背景出现,主要由于IS26介导的blaOXA-1和blaCTX-M-1组基因扩增伴随孔蛋白失活。
- 携带并扩增β-内酰胺酶基因的离散模块化可移动单元从染色体IS26结合转座子胞内移动并插入孔蛋白基因,同时增加β-内酰胺酶基因拷贝数并灭活孔蛋白。
- 在厄他培南存在下传代临床ESBL-E分离株可重现碳青霉烯耐药表型和TU介导的β-内酰胺酶基因扩增。
- 临床非CP-CRE分离株在无厄他培南暴露时碳青霉烯耐药表型稳定。
临床怎么用
- 对ESBL-E菌血症患者,尤其复发者,应警惕非碳青霉烯酶CRE的新发。
- 长读长测序有助于识别IS26等移动遗传元件介导的耐药机制。
- 非CP-CRE的碳青霉烯耐药表型在无药物压力下稳定,需持续监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately half of clinical carbapenem-resistant Enterobacterales (CRE) isolates lack carbapenem-hydrolysing enzymes and develop carbapenem resistance through alternative mechanisms. OBJECTIVES: To elucidate development of carbapenem resistance mechanisms from clonal, recurrent ESBL-positive Enterobacterales (ESBL-E) bacteraemia isolates in a vulnerable patient population. METHODS: This study investigated a cohort of ESBL-E bacteraemia cases in Houston, TX, USA. Oxford Nanopore Technologies long-read and Illumina short-read sequencing data were used for comparative genomic analysis. Serial passaging experiments were performed on a set of clinical ST131 Escherichia coli isolates to recapitulate in vivo observations. Quantitative PCR (qPCR) and qRT-PCR were used to determine copy number and transcript levels of β-lactamase genes, respectively. RESULTS: Non-carbapenemase-producing CRE (non-CP-CRE) clinical isolates emerged from an ESBL-E background through a concurrence of primarily IS26-mediated amplifications of blaOXA-1 and blaCTX-M-1 group genes coupled with porin inactivation. The discrete, modular translocatable units (TUs) that carried and amplified β-lactamase genes mobilized intracellularly from a chromosomal, IS26-bound transposon and inserted within porin genes, thereby increasing β-lactamase gene copy number and inactivating porins concurrently. The carbapenem resistance phenotype and TU-mediated β-lactamase gene amplification were recapitulated by passaging a clinical ESBL-E isolate in the presence of ertapenem. Clinical non-CP-CRE isolates had stable carbapenem resistance phenotypes in the absence of ertapenem exposure. CONCLUSIONS: These data demonstrate IS26-mediated mechanisms underlying β-lactamase gene amplification with concurrent outer membrane porin disruption driving emergence of clinical non-CP-CRE. Furthermore, these amplifications were stable in the absence of antimicrobial pressure. Long-read sequencing can be utilized to identify unique mobile genetic element mechanisms that drive antimicrobial resistance.
引用
- Shropshire WC, Aitken SL, Pifer R, et al. IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort. J Antimicrob Chemother. 2021. PMID: 33164081. doi:10.1093/jac/dkaa447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。